Medicine and Dentistry
Acute Kidney Injury
29%
Adipose Tissue
14%
ANCA Associated Vasculitis
24%
Biological Marker
10%
Biopsy Technique
60%
Clinical Trial
54%
Clinician
17%
Cohort Effect
17%
Continuous Renal Replacement Therapy
24%
COVID-19
9%
Creatinine
18%
Dasatinib
49%
Diabetic Nephropathy
100%
Disease Activity
24%
End Stage Renal Disease
16%
Enzyme Linked Immunosorbent Assay
12%
Focal Segmental Glomerulosclerosis
23%
Glomerular Filtration Rate
14%
Glomerulonephritis
74%
Glomerulopathy
79%
Graft Survival
16%
Immunoglobulin A Nephropathy
38%
Immunosuppressive Treatment
20%
Ketogenic Diet
24%
Kidney Allograft
26%
Kidney Transplantation
32%
Language Processing
24%
Lupus Nephritis
32%
Macrophage
9%
Maintenance Therapy
11%
Membranous Glomerulonephritis
41%
Microhematuria
24%
Minimal Change Disease
24%
Myeloperoxidase
24%
Nephropathy
47%
Nephrotic Syndrome
12%
New-Onset Atrial Fibrillation
24%
Oxalic Acid
24%
Phospholipase A2 Receptor
45%
Precursor
9%
Proteinuria
21%
Pulmonary Hemorrhage
19%
Pulmonary-Renal Syndrome
24%
Quercetin
49%
Receptor Antibody
24%
Recurrent Disease
32%
Renal Biopsy
71%
Renal Replacement Therapy
10%
Uncaria tomentosa
24%
Urinary System
29%
Keyphrases
Acute Kidney Injury
24%
Antibody Test
15%
Bicinchoninic Acid Assay
12%
Biopsy Pathology
24%
Cleveland Clinic
24%
Clinical Expertise
12%
Clinical Trials
24%
Continuous Renal Replacement Therapy
24%
Dasatinib
24%
De-identified Data
24%
Diabetic Kidney Disease
37%
Early Diagnosis
12%
Early Intervention
12%
End-stage Kidney Disease
24%
Endocapillary Hypercellularity
24%
Etiology
12%
Exostosin
12%
Fibrillary Glomerulonephritis
24%
Florida
15%
Glomerular Disease
37%
Glomerulonephritis
12%
Graft Loss
12%
Hypertensive Kidney Disease
12%
Idiopathic Membranous Nephropathy
24%
Immunosuppression
12%
Improved Outcomes
12%
Ketogenic Diet
24%
Kidney Allograft
24%
Kidney Involvement
24%
Membranous Nephropathy
15%
Myeloperoxidase-ANCA
24%
New-onset Atrial Fibrillation
24%
Non-invasive Diagnosis
24%
Nuclear Magnetic Resonance Metabolomics
12%
Phospholipase A2 Receptor (PLA2R)
24%
Prompt Treatment
12%
Quercetin
24%
Recurrent Disease
12%
Recurrent Glomerulonephritis
24%
Recurring
12%
Regional Grant
12%
Renal Allograft
12%
Renal Allograft Survival
12%
Renal Replacement Therapy
12%
Renal Transplantation
12%
Secondary Causes
12%
Senescent Cells
24%
Senolytics
24%
Trimethylsilyl
24%
Uncaria Tomentosa
24%